Allergan reported $4.3 billion in fourth quarter GAAP net revenues, a 12% increase over the previous year’s fourth quarter, according to a company press release. Full-year net revenues increased to $15.9 billion.
GAAP operating loss from continuing operations was $90.5 million in the fourth quarter and $5.9 billion for the year, which the company attributed to impairment charges and research and development costs.
Revenues for the eye care arm increased to $671.7 million in 2017’s fourth quarter compared with $660.1 million in 2016’s fourth quarter. Restasis net revenues
Uncategorized